Alves, Pedro UrbanoVinhas, RaquelFernandes, Alexandra R.Birol, Semra ZuhalTrabzon, LeventBernacka-Wojcik, IwonaIgreja, RuiLopes, PauloBaptista, Pedro VianaÁguas, HugoFortunato, ElviraMartins, Rodrigo2019-03-122019-03-122018-12-012045-2322PURE: 3801069PURE UUID: f3af0a31-213c-4dfc-925f-b009a48ddce1Scopus: 85040465519ORCID: /0000-0001-5255-7095/work/54824819WOS: 000419673100017PubMed: 29321602PubMedCentral: PMC5762653ORCID: /0000-0001-7350-649X/work/59227440ORCID: /0000-0002-4202-7047/work/50749265ORCID: /0000-0002-6608-3422/work/69844450ORCID: /0000-0003-2054-4438/work/89984006http://www.scopus.com/inward/record.url?scp=85040465519&partnerID=8YFLogxKsem pdf conforme despacho. FCT - Portuguese Foundation for Science and Technology under the project number POCI-01-0145-FEDER-007688, and project DISERTOX, Reference PTDC/CTM-NAN/2912/2014. co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728.Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors.2430811engGeneralSDG 3 - Good Health and Well-beingjournal article10.1038/s41598-017-18725-9https://www.scopus.com/pages/publications/85040465519